Physician profile
Curtis Clint Ephesians Phillips
NPI 1811285737
$1,560.14
in general payments reported to CMS, 2019-2025
11 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Addiction Psychiatry provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.18 · 2020: $20.94 · 2022: $298 · 2023: $408 · 2024: $557 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $701.39 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $306.58 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $164.83 | 2020-2024 | Invega Sustenna |
| Axsome Therapeutics, INC. | $105.31 | 2024 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $96.50 | 2022 | |
| Indivior INC. | $62.60 | 2024 | Sublocade |
| Braeburn INC. | $34.58 | 2024 | Brixadi |
| Uswm, LLC | $27.17 | 2024 | Lucemyra |
| Sunovion Pharmaceuticals INC. | $24.01 | 2019 | |
| Vanda Pharmaceuticals INC. | $21.62 | 2019 | |
| Neurocrine Biosciences, INC. | $15.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.